Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Non-Current Deffered Revenue (2023 - 2025)

Metagenomi (MGX) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 70.8% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 70.8% decrease, with the full-year FY2025 number at $3.0 million, down 70.8% from a year prior.
  • Non-Current Deffered Revenue was $3.0 million for Q4 2025 at Metagenomi, up from $1.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $30.9 million in Q4 2023 to a low of $1.9 million in Q3 2025.
  • A 3-year average of $11.6 million and a median of $10.2 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 66.9% in 2024, then crashed 84.75% in 2025.
  • Metagenomi's Non-Current Deffered Revenue stood at $30.9 million in 2023, then plummeted by 66.9% to $10.2 million in 2024, then plummeted by 70.8% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Non-Current Deffered Revenue are $3.0 million (Q4 2025), $1.9 million (Q3 2025), and $3.6 million (Q2 2025).